

FRIDAY, JULY 29, 2022

INTRODUCTION, WELCOME AND COURSE GOALS:

7:00 AM: Amanda Fader and Andy Satin

ENDOMETRIAL CANCER: TRENDS, RACIAL DISPARITIES, PREVENTION

Moderators: Anna Beavis and Larissa Meyer

7:10 AM U.S. & Global Endometrial Cancer Trends: What is driving these disturbing statistics? Amanda Fader

7:25 AM: The Obesity Problem: Epidemiologic Trends and Screening Models: Anna Beavis & Anne Rositch

7:50 AM: The Obesity Problem: Molecular and Clinical Drivers: Vickie Bae Jump and Paola Gehrig

8:15 AM: Endometrial Cancer Prevention: Biomarkers, Bariatric Surgery & IUDs: Larissa Meyer

8:40 AM: Racial/ethnic Inequities in Endometrial Cancer Incidence, Mortality and Patient Care: Who is at the Highest Risk? Yovani "Jo" Casablanca

9:05 AM: Novel Endometrial Cancer Detection Strategies: Jonathan Dudley & Amanda Fader

9:25 AM: Endometrial Cancer Advocacy and Awareness Campaigns: Ginger Gardner

9:45 AM: Q&A

10:00 AM: BREAK

ENDOMETRIAL CANCER: CURRENT TREATMENT LANDSCAPE

Moderators: Gini Fleming and Stephanie Gaillard

10:15 AM: Molecular Drivers in Endometrial Cancer: Ie-Ming Shih

10:30 AM: Precision Medicine in Endometrial Cancer: TCGA, PROMIS et al Jessica McAlpine

10:55 AM: Practical Endometrial Cancer Molecular Testing Considerations: Matthew Powell

11:20 AM: Updates/unanswered questions in early-stage, high risk carcinoma: Ann Klopp

11:45 AM: Trials in advanced/chemo-naïve recurrent disease: Ramez Eskander

12:10 AM: Treatment of recurrent endometrial cancer: Brian Slomovitz

12:25 PM: Q&A

12:45 PM: LUNCH

IMMUNOTHERAPY AND ENDOCRINE TARGETS

Moderators: Matthew Powell and Rebecca Stone

1:15 PM: Immunotherapy trials & unanswered questions: Vicky Makker

1:40 PM: Immunotherapy and radiation combination trials in endometrial cancer: A potential synergy? Ursula Matulonis and Akila Viswanathan

2:05 PM: POLE Mutated Tumors: What Do We Do? Benoit Rousseau

2:30 PM: Endocrine therapy perspectives and research partnerships: Linda Duska and Kimberly Leslie

2:55 PM: Fertility-sparing Treatments and Novel Therapies: Shannon Westin

3:20 PM: Q&A

3:30 PM: BREAK

RARE TUMORS & NEW TARGETS

Moderators: Joyce Liu and Debra Richardson

3:40 PM: Utilizing preclinical models to develop targeted therapies for rare endometrial cancers: Sarah Adams and Stephanie Gaillard

4:05 PM: Uterine serous carcinoma: updates/unanswered questions in early/advanced-stage disease: Britt Erickson

4:05 PM: Uterine serous carcinoma: updates/unanswered questions in recurrent disease: Joyce Liu

4:25 PM: Uterine carcinosarcoma: updates/unanswered questions: Matthew Powell

4:45 PM: Uterine clear cell and undifferentiated cancers: updates/unanswered questions Debra Richardson

5:05 PM: Utilizing preclinical models to develop targeted therapies for rare endometrial cancers: Sarah Adams and Stephanie Gaillard

5:30 PM Q&A

5:45:PM ADJOURN

SATURDAY, JULY 30

Registries and Research Groups to Tackle the Problem

Moderators: Ursula Matulonis, Bradley Monk and Kathleen Moore

6:45 AM: Breakfast

7:00 AM: Real-world registries/datasets to solve real-world endometrial cancer problems:

Angeles Secord

7:20 AM: Cancer Moonshot: Updates in Endometrial Cancer: Kathleen Darcy

7:40 AM: GOG 210 Dataset Opportunities for Rare Tumors: David Mutch

8:00 AM: Novel Window of Opportunity Studies: Rebecca Stone

8:20AM: Debate: What is the best design of rare tumor trials: histology or biomarker-based? Jubilee

Brown vs. Gini Fleming

8:45 AM: Q&A

9:00 AM: BREAK

9:15 AM: NCCN Guidelines for Uterine Neoplasms: Where are We Headed? Nadeem Abu Rustum

9:35 AM: Perspectives on Rare Endometrial Cancer Trial Development: Panel NCI, NRG Oncology, GOG

Elise Kohn, Matthew Powell and Bhavana Pothuri

10:05 AM: Are registration trials in rare gynecologic cancers possible? Bradley Monk and Kathleen

Moore

10:35 AM: Q&A

10:45 AM: SYMPOSIUM ADJOURNED and BREAK for Faculty

RESEARCH BREAK-OUT SESSIONS with SYMPOSIA FACULTY (Invited faculty only, CMEs not offered)

11:15 AM: Breakout sessions with translational scientists and clinical trialists to develop a white paper and define research priorities in rare endometrial tumors/moving the needle on endometrial cancer mortality, further developing consortium-based research projects

12:30 PM Regroup and small group reports of breakout teams

1:00 PM: MEETING ADJOURNED